Pharmaceutical

Knight Therapeutics (TSX:GUD) a leading Canadian specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2017. All dollar amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. As quoted in the press release: “We are pleased to report that …

Knight Therapeutics (TSX:GUD) a leading Canadian specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2017. All dollar amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

As quoted in the press release:

“We are pleased to report that 2017 marked a pivotal year for Knight’s simple yet meaningful mission to make people better through the products we sell. In 2017, we launched our first commercial prescription pharmaceutical in Canada,” said Jonathan Ross Goodman, CEO of Knight. “While we continue to advance our pipeline, building Canada’s leading specialty pharmaceutical company is a marathon, not a sprint, and will take time. We continue to view our balance sheet as a significant competitive advantage and remain confident that our patience and focus on securing the rights to innovative products at fair prices will pay healthy dividends in the future.”

Click here to read the full press release.

Featured

MARKETS

Markets
TSX21058.18-146.98
TSXV890.35-10.52
DOW34715.39-313.26
S&P 5004482.73-50.03
NASD14154.02-186.23
ASX7342.40+9.90

COMMODITIES

Commodities
Gold1840.85+2.00
Silver24.44+0.06
Copper4.51-0.07
Palladium2041.50+7.50
Platinum1035.50-0.49
Oil83.75-1.80
Heating Oil2.58-0.04
Natural Gas3.88+0.08

DOWNLOAD FREE REPORTS

×